Editing Xeroderma pigmentosum (section)

== Treatment ==
[[Image:XP Child in UV-protective Clothing.jpg|thumb|Child in UV-protective clothing during initial stages of XP]]
There is no cure for the disorder; all treatment is symptomatic or preventive. Symptoms can be avoided or controlled by completely avoiding exposure to sunlight, either by staying indoors or wearing protective clothing and using [[sunscreen]] when outdoors.<ref>{{Cite book |last=Nussbaum |first=Robert |title=Genetics in Medicine |last2=McInnes |first2=Roderick |last3=Willard |first3=Huntington |date=2016-01-01 |publisher=Elsevier |isbn=978-14377-0696-3 |name-list-style=vanc}}</ref> [[Keratosis]] can also be treated by using [[cryotherapy]] or [[fluorouracil]].<ref name="Halpern_2008">{{Cite journal |vauthors=Halpern J, Hopping B, Brostoff JM |date=October 2008 |title=Photosensitivity, corneal scarring and developmental delay: Xeroderma Pigmentosum in a tropical country |journal=Cases Journal |volume=1 |issue=1 |pages=254 |doi=10.1186/1757-1626-1-254 |pmc=2577106 |pmid=18937855 |doi-access=free}}</ref> In more severe cases of XP, even minuscule amounts of UV light, for example, from covered windows or fluorescent bulbs, can be very dangerous and trigger symptoms.<ref>{{Cite magazine |date=September 24, 2014 |title=Xeroderma pigmentosum |url=https://www.indiatoday.in/lifestyle/health/story/story/xeroderma-pigmentosum/1/391127-300570-2014-09-24 |access-date=2020-07-05 |magazine=India Today |language=en}}</ref>

On September 10, 2020, Clinuvel Pharmaceuticals announced that it was investigating the use of its FDA-approved flagship drug [[Afamelanotide|Scenesse]] as a potential treatment to increase pain-free light exposure for patients with xeroderma pigmentosum.<ref>{{Cite web |title=SCENESSE® (afamelanotide 16mg) – Welcome to CLINUVEL |url=https://www.clinuvel.com/pharmaceutical/scenesse/scenesse |url-status=dead |archive-url=https://web.archive.org/web/20201020100319/https://www.clinuvel.com/pharmaceutical/scenesse/scenesse |archive-date=2020-10-20 |access-date=2020-09-24}}</ref><ref>{{Cite web |last=Commissioner |first=Office of the |date=2020-03-24 |title=FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder |url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder |access-date=2020-09-24 |website=FDA |language=en}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref><ref>{{Cite web |title=Scenesse (afamelanotide) for adults with a history of phototoxic reactions from EPP |url=https://scenesse.com/ |access-date=2020-09-24 |website=SCENESSE® (Afamelanotide) |language=en-US}}</ref>